Literature DB >> 2284101

Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.

S L Cohn1, H Salwen, M W Quasney, N Ikegaki, J M Cowan, C V Herst, R H Kennett, S T Rosen, J A DiGiuseppe, G M Brodeur.   

Abstract

Genomic amplification of the oncogene N-myc is associated with rapid tumor progression and poor prognosis in patients with neuroblastoma (NB). However, 40% of NBs which lack N-myc amplification are also clinically aggressive. Factors other than N-myc copy number must therefore play a role in determining tumor progression in these NBs. We have established an unusual human NB cell line (NBL-S) from the primary tumor of a patient with rapidly progressive disease which lacks N-myc amplification. The doubling time in vitro (48 h) and the time from injection of 2 x 10(7) cells to detectable tumors in nude mice (46 days) in similar to NB cell lines with amplified N-myc. However, karyotype analysis reveals no evidence of double minutes (DMs), homogeneously staining regions (HSRs), or chromosome 1p deletions, features commonly seen in NB cell lines. The cells have the cell surface phenotype typical of N-myc amplified NB (HLA-A,B,C negative and HSAN 1.2 positive), and similar to other NB cell lines, N-myc RNA and protein are expressed. Interestingly, the half-life of the N-myc protein in NBL-S is prolonged (approximately 100 min) compared to the short N-myc protein half-life previously described in N-myc amplified NB cell lines (approximately 30 min). Because N-myc protein is thought to have a regulatory role, prolongation of the half-life of this protein may be an important factor in the regulation of growth in NBs which lack N-myc amplification and rapidly progress.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2284101

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma.

Authors:  R Amitay; D Nass; D Meitar; I Goldberg; B Davidson; L Trakhtenbrot; F Brok-Simoni; A Ben-Ze'ev; G Rechavi; Y Kaufmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Patterns of oncogene activation in human neuroblastoma cells.

Authors:  R Corvi; L Savelyeva; M Schwab
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.

Authors:  Sara Cattelani; Giovanna Ferrari-Amorotti; Sara Galavotti; Raffaella Defferrari; Barbara Tanno; Samantha Cialfi; Jenny Vergalli; Valentina Fragliasso; Clara Guerzoni; Gloria Manzotti; Angela Rachele Soliera; Chiara Menin; Roberta Bertorelle; Heather P McDowell; Alessandro Inserra; Maria Luisa Belli; Luigi Varesio; Deborah Tweddle; Gian Paolo Tonini; Pierluigi Altavista; Carlo Dominici; Giuseppe Raschellà; Bruno Calabretta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

5.  Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Authors:  Alexandre Chlenski; Chanyoung Park; Marija Dobratic; Helen R Salwen; Brian Budke; Jae-Hyun Park; Ryan Miller; Mark A Applebaum; Emma Wilkinson; Yusuke Nakamura; Philip P Connell; Susan L Cohn
Journal:  Mol Cancer Ther       Date:  2019-01-23       Impact factor: 6.261

6.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Authors:  Louis Chesler; Chris Schlieve; David D Goldenberg; Anna Kenney; Grace Kim; Alex McMillan; Katherine K Matthay; David Rowitch; William A Weiss
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

7.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Authors:  Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors.

Authors:  D R Keim; N Hailat; R Kuick; C P Reynolds; G M Brodeur; R C Seeger; S M Hanash
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

9.  The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc.

Authors:  Jun Li; Leo Kretzner
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

10.  A novel intron element operates posttranscriptionally To regulate human N-myc expression.

Authors:  L E Sivak; G Pont-Kingdon; K Le; G Mayr; K F Tai; B T Stevens; W L Carroll
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.